ALS News TodayOral ALS Treatment Lowers Toxic Protein Levels, Extends Survival

⚠️ Small Study / Early Comparative Evidence

PrimeC met its Phase 2b primary biomarker endpoint by lowering TDP-43 levels after six months in adults with ALS. The company-reported findings add biomarker support to earlier functional and survival signals but require Phase 3 confirmation.

Clinical Considerations

• PARADIGM randomized 68 adults with ALS to PrimeC or placebo, followed by an open-label extension.
• TDP-43 reductions were measured in neuron-derived extracellular vesicles, distinguishing nerve-derived protein signals from peripheral sources.
• Earlier PARADIGM analyses reported 32.8% to 36.5% slower functional decline across longer follow-up intervals.
• Long-term data suggested an approximately 15-month median survival extension, with no new safety concerns reported.

Practice Applications

• Interpret PrimeC as an investigational ALS therapy pending Phase 3 validation.
• Recognize TDP-43 reduction as a biomarker signal, not established clinical proof.
• Monitor PARAGON enrollment and confirmatory efficacy, safety, and survival outcomes.
• Avoid overstating treatment implications before pivotal trial results are available.